Status:
UNKNOWN
Effect of PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on Acute Rejection After Liver Transplantation in Patients With Hepatocellular Carcinoma
Lead Sponsor:
Beijing Tsinghua Chang Gung Hospital
Conditions:
Hepatocellular Carcinoma
Acute Rejection
Eligibility:
All Genders
18-70 years
Brief Summary
This study is a single-center, prospective, non-interventional cohort study based on the real world data.In this study, 30 patients with a history of PD-1/PD-L1 monotherapy prior to liver transplantat...
Eligibility Criteria
Inclusion
- age between 18 and 70 years,
- Eastern Cooperative Oncology Group (ECOG) performance score ≤3,
- voluntarily participate, totally understand in the study and sign the Informed Consent Form (ICF),
- hepatopathology confirmed hepatocellular carcinoma after liver transplantation, 5）patients with hepatocellular carcinoma treated with PD1/PD-L1 monoclonal antibody prior to liver transplantation,
- 6）PD-1/PD-L1 monotherapy needs to be used ≥ 2 times (The patients were divided into observation and control group according to whether received PD-1/PD-L1 monoclonal antibody treatment before liver transplantation)
Exclusion
- patients with incomplete clinicopathological data,
- post-transplantation ≥6months,
- PD-1/PD-L1 monotherapy required for oncological reasons after liver transplantation.
Key Trial Info
Start Date :
March 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05411926
Start Date
March 17 2021
End Date
September 1 2023
Last Update
June 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China, 102218